To clarify the role of ERK1/2 in TGF‐β‐induced increase in EGFR expression, we pretreated the breast cancer cells with the ERK1/2 signaling inhibitor PD98059 and then stimulated these cells with TGF‐β. Here, MAPK3 is linked to breast carcinoma.